Case Studies

Context & Objective

• A leading pharmaceutical corporation encountered considerable challenge in identification of candidate drug targets for a cutting-edge drug modality, necessitating the deployment of an innovative strategy to effectively harness their proprietary technology platform.
• We collaborated with the client to help address the challenge by employing our advanced AI platform to expedite the resolution of these issues with remarkable efficiency.

Approach & Solution

• Our multidisciplinary team, comprising esteemed scientists, molecular biologists, data scientists and pharmacologists, devised a custom workflow utilizing the capabilities of our proprietary AI platform RxAgentAI.
• The strategy incorporated an AI-driven methodology to identify novel candidate targets for the emergent drug modality, followed by meticulous manual validation. This approach leveraged specialized expertise to amplify its therapeutic potential, substantially expanding the scope of therapeutic possibilities.
• Utilizing our AI platforms along with an internal extensive database, we deployed advanced methodologies such as LLMs to meticulously search through various public scientific literature databases including PubMed, Open Targets, Propedia, among others.
• This cutting-edge method facilitated the discovery of novel therapeutic candidates which underwent subsequent manual validation and expansion of their therapeutic potential across diverse diseases using their association to the target genes.
• Our scientifically substantiated frameworks, which incorporate evidence-based metrics within our AI platforms, aided in the prioritization of high-value therapeutics.

Outcome & Impact

This strategy culminated in the successful identification of numerous promising candidate-Drug-Target-Disease triads. Consequently, the project not only fulfilled but surpassed the client’s expectations, expedited drug discovery by streamlining the identification process, reduced time-to-discovery, and enhanced therapeutic innovation.